®Synulox LC

Each syringe contains 50 mg Clavulanic acid as potassium clavulanate Ph.Eur., 200 mg Amoxicillin as amoxicillin trihydrate Ph.Eur. and 10 mg Prednisolone Ph.Eur. swab teat  end with surgical spirit before treatment.

For use in clinical cases of mastitis in lactating cattle including cases associated with infections with the following pathogens: Staphylococci (including β-lactamase producing strains), Streptococci (including S. agalactiae, S. dysgalactiae, and S. uberis), Escherichia coli (including β-lactamase-producing strains).

Before the infusion is made, the teat end should be cleaned and disinfected. The contents of one syringe should be infused into each affected quarter via the teat canal, immediately after milking, at 12 hour intervals for three consecutive milkings. In cases of infections caused by Staphylococcus aureus, a longer course of antibacterial therapy may be required. Therefore, overall treatment length must be at the veterinary surgeon’s discretion but should be long enough to ensure complete resolution of the intramammary infection.

Meat and offal: 7 days. Milk: 48 hours, i.e. 4 milkings with 2 times a day milking.

Do not use in animals which are known to be hypersensitive to β-lactamase antibiotics. Do not use in cases associated with Pseudomonas. Synulox Lactating Cow should be used for treatment of clinical mastitis only. Swab teat end with an appropriate disinfectant before treatment. Use of the product should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria and take into account official and local antimicrobial policies. The use of the product should preferably be based on susceptibility tests. Avoid use of the product in herds where no β-lactamase producing Staphylococci strains have been isolated. Veterinarians should strive to use narrow spectrum antibiotics if possible. Inappropriate use of the product may increase the prevalence of bacteria resistant to β-lactam antibiotics and may decrease the effectiveness of treatment with β-lactam antibiotics, due to the potential for cross-resistance.